Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Return on Sales (2022 - 2026)

bioAffinity Technologies has reported Return on Sales over the past 5 years, most recently at 0.03% for Q1 2026.

  • Quarterly Return on Sales fell 1.0% to 0.03% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.03% through Mar 2026, down 2.0% year-over-year, with the annual reading at 0.02% for FY2025, 1.0% down from the prior year.
  • Return on Sales was 0.03% for Q1 2026 at bioAffinity Technologies, down from 0.02% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.01% in Q1 2024 and troughed at 42.78% in Q3 2022.
  • The 5-year median for Return on Sales is 0.03% (2025), against an average of 4.27%.
  • The largest YoY upside for Return on Sales was 4270bps in 2023 against a maximum downside of -21bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 7.14% in 2022, then surged by 100bps to 0.01% in 2023, then dropped by -25bps to 0.01% in 2024, then plummeted by -47bps to 0.02% in 2025, then crashed by -36bps to 0.03% in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Return on Sales are 0.03% (Q1 2026), 0.02% (Q4 2025), and 0.03% (Q3 2025).